Dressings comprising platelet lysate

Abstract

A dressing comprises a delivery vehicle and platelet lysate. The dressing can also include an antimicrobial agent, a hemostatic agent, and a binder. It is contemplated that the dressing can be used for expediting hemostasis, improving antimicrobial activity, minimizing fluid loss, and accelerating wound healing when applied to a wound. The dressing would be useful in applications including military in-theater medical care and for conditions such as diabetic foot ulcers, as well as other applications.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part of PCT Application Number PCT / US17 / 39918, filed Jun. 29, 2017, which claims priority to U.S. Provisional Patent Application Ser. No. 62 / 356,163, filed on Jun. 29, 2016, which is hereby fully incorporated by reference.BACKGROUND[0002]The present disclosure relates to dressings that can be used to simultaneously address complex trauma, namely blood loss, incidence of infection, prevention of wound progression, tissue preservation and restoration, revascularization, and wound healing. Such technology can be useful in military theatres, humanitarian assistance, disaster relief operations, and treatment of acute and chronic conditions affecting military and civilian populations. The dressings include human platelet lysate, and are useful for various applications and purposes.[0003]New products that address critical aspects of traumatic wound care and can be easily used and deployed in large numbers mu...

AI Technical Summary

Benefits of technology

The present patent is about various dressings made from a delivery vehicle and human platelet lysate (hPL) that can be used for protecting wounds and treating other applications. The dressings come in the form of bandages that can speed up wound healing, prevent infection, and minimize fluid loss. The bandage is designed to be resilient and can deliver human-derived growth factors and agents to prevent infection and blood loss. The dressings can also come in liquid, cream, gel, shampoo, foam, or aerosol form.

Problems solved by technology

For example, the use of improvised explosive devices (IEDs) has introduced medical challenges related to severe blast-induced injuries.

IEDs use incendiary materials and are frequently contaminated with soil or sewage due to their source materials and / or placement.

As a result, severe burns and lacerations with consequential infection are common.

The loss of tissue viability and high incidence of infection has contributed to elevated limb amputation rates in military personnel who survive IED-induced injuries.

Similar concerns arise in the treatment of diabetic foot ulcers, which is one of several complications of diabetes that markedly impairs quality of life, shortens lifespan, and constitutes an enormous societal economic burden.

Various estimates indicate that the cost of DFU treatment consumes 25 to 50% of the total cost of all diabetes treatment.

Unfortunately, 45% to 55% of these patients die within 5 years of the amputation.

Despite a clearer understanding of the causal factors leading to limb loss and an increasing consensus on the management of various aspects of diabetic foot care in recent years healing rates for DFUs remain frustratingly low.

Unfortunately, current treatments result in healing rates of approximately 25% after 12 weeks and 30% after 20 weeks.

Disappointingly, these interventions provide only moderate improvement over standard treatments (generally only 15-20%), are considerably more expensive, and are associated with significant safety concerns.

For example, becaplermin increased the risk of cancer mortality in patients.

Other interventions, including hyperbaric oxygen and negative pressure devices, have shown promise in promoting DFU healing, but have yet to be tested in large clinical trials.

Images